Co-Founder and CEO Pierluigi Paracchi describes the terms of the convertible bond raise, which gives the investor, ENEA Tech and Biomedical, the opporutnity to convert to equity in three years. He also provides an update on the progress of dosing renal cell carcinoma patients in the clinic, and what we can expect from the trial throughout the rest of the year.
View all episodes
By BiotechTV
4.3
66 ratings
Co-Founder and CEO Pierluigi Paracchi describes the terms of the convertible bond raise, which gives the investor, ENEA Tech and Biomedical, the opporutnity to convert to equity in three years. He also provides an update on the progress of dosing renal cell carcinoma patients in the clinic, and what we can expect from the trial throughout the rest of the year.
3,222 Listeners
1,910 Listeners
124 Listeners
324 Listeners
61 Listeners
9,957 Listeners
86 Listeners
34 Listeners
353 Listeners
19 Listeners
60 Listeners
512 Listeners
41 Listeners
0 Listeners
4 Listeners
2 Listeners
6 Listeners
48 Listeners